Replies to post #389376 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Hi ATL.
Well the results of that combo trial with Keytruda should certainly be interesting.
But I have my doubts about whether the use of Keytruda as the neo-adjuvant will actually work. It may work for a minority, but it might also introduce significant toxicity in others.
We know about the phenomenon of ICI-related hyper-progression in several other cancers, notably NSCLC; it may also prove to be a real factor in GBM.

I came across this reference recently:-

"In IDH1 wild type GBM, the median survival rate of patients with CDK4/MDM2 co-amplification is 6.6 months after diagnosis, while the median survival rate of patients without an CDK4/MDM2 co-amplification is 12.7 months"

https://www.frontiersin.org/articles/10.3389/fmolb.2020.562798/full

Well, in that one sentence, we suddenly have another biomarker expression that may have important prognostic significance in GBM!

I'm also aware that there is a putative association between MDM2 amplification and increased likelihood of ICI-related hyper-progression.

Patient experiences of Keytruda in NSCLC:-

https://www.drugs.com/comments/pembrolizumab/keytruda-for-non-small-cell-lung-cancer.html#

Perhaps you can see why I have doubts...